| ¿µ¹® | thrombin | ÇÑ±Û | Æ®·Òºó |
|---|---|---|---|
| ¼³¸í | ÇÁ·ÎÆ®·Òºó¿¡¼ À¯·¡µÇ´Â È¿¼Ò·Î¼, ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼ÒÀ¸·Î º¯È¯½ÃÄÑ Ç÷¾×ÀÀ°í¸¦ ¿Ï¼º½ÃŲ´Ù. |
||
| ¿µ¹® | anti-inflammatory agent | ÇÑ±Û | Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à |
|---|---|---|---|
| ¼³¸í | ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇÏ´Â ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇÏ°Ô ÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ ÀÖ´Â ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈÁ¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³ÈÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| JVP | [POMD P 49 - 52] 1) Jugular Vein Pressure 2) Jugular Venous Pulse ... |
| AT III | angiotensin III; antithrombin III |
| ML | I, II, III, IV mucolipidosis I, II, III, IV |
| AB, Ab | 1) Anti-body; Ç×ü 2) Anti-Biotics; Ç×»ýÁ¦ |
| AT III | Anti-thrombin III |
|---|---|
| TAT | Thrombin antithrombin III complex |
| TAT | Thrombin-Antithrombin III |
| A III | Angiotensin III |
| ANG III | Angiotensin III |
pseudounipolar bipolar III disorder
transverse facial vein
| receptors, thrombin | Cell surface proteins that specifically bind thrombin and trigger changes in the behaviour of blood cells. There are at least two types of thrombin receptors on platelets. The higher affinity receptors mediate the inhibition of stimulated adenylate cyclase, the secretion of acid hydrolases, and the activation of phospholipase a2. The lower affinity receptors are linked to phospholipase c and trigger platelet aggregation and exposure of fibrinogen binding sites. A human platelet thrombin receptor has been cloned and is a member of the family of peptide receptors. There are also thrombin receptors on endothelial cells and smooth muscle cells. (12 Dec 1998) |
|---|---|
| human thrombin | Thrombin obtained from human plasma by precipitation with suitable salts and organic solvents; same uses as thrombin. (05 Mar 2000) |
| thrombin | <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly. Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion. (18 Nov 1997) |
| thrombin time | Test of the conversion of fibrinogen to fibrin by thrombin in which clotting time of plasma mixed with a thrombin solution is measured. Time is prolonged by afibrinogenaemia, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, heparin. Reptilase, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin. (12 Dec 1998) |
| agent, anti-infective | Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. (12 Dec 1998) |
| anti- | <prefix> A prefix meaning against, opposite or opposed to, contrary, or in place of, in relation to symptoms and diseases, curative. Often used in composition in many English words. It is often shortened to ant-; as, antacid, antarctic. Origin: Gr. against, opposite, instead of. Source: Websters Dictionary (20 Jun 2000) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
| anti-asthmatic agents | Drugs that are used to treat asthma. (12 Dec 1998) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| anti-basement membrane glomerulonephritis | Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome. (05 Mar 2000) |
| anti-basement membrane nephritis | Glomerulonephritis produced by autologous or heterologous antibodies to the glomerular capillary basement membranes, the latter known as anti-kidney serum nephritis. (05 Mar 2000) |
| anti-black-tongue factor | A precursor of NAD, that is a product of the oxidation of nicotine. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|---|---|---|---|
|
¾ÈƼƮ·Òºó¥²ÁÖ500IU - »õâ
|
³ì½ÊÀÚ |
A35504531 | Antithrombin III, human | Àü¹®ÀǾàǰ | ±Þ¿© |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|